Reaction

Heart Valve Incompetence reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,839 reports · 72 co-occurring drugs

As of the last recalculation, Heart Valve Incompetence appears in 2,839 FAERS reports alongside 72 co-occurring drug terms. The strongest observed disproportionality signal is OCTREOTIDE ACETATE (PRR 13.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Octreotide Acetate	56	13.7	13.7
Terazosin Hydrochloride	16	13.3	13.3
Sacubitril And Valsartan	158	10.5	10.5
Agalsidase Beta	12	9.6	9.6
Captopril	12	9.2	9.2
Norepinephrine	11	7.6	7.6
Rocuronium Bromide	12	7.5	7.5
Eplerenone	13	7.5	7.5
Psyllium Husk	10	7.4	7.5
Telmisartan	18	7.4	7.4
Bumetanide	26	7.3	7.3
Basiliximab	11	6.9	6.9
Indomethacin	12	6.7	6.7
Metolazone	10	6.5	6.5
Cyclobenzaprine Hydrochloride	7	5.7	5.7
Metoprolol Tartrate Injection	141	5.7	5.7
Ranolazine	8	5.6	5.6
Norepinephrine Bitartrate	11	5.6	5.6
Lanreotide Acetate	6	5.6	5.6
Digoxin	54	5.6	5.6
Metoprolol	181	5.5	5.5
Metoprolol Tartrate	192	5.4	5.5
Bicalutamide	11	5.3	5.3
Bosentan	35	5.1	5.1
Irbesartan	31	5.1	5.1
Metoroprolol Tartrate	45	5.1	5.1
Gentamicin	9	5.1	5.1
Dronedarone	7	5.0	5.0
Raloxifene Hydrochloride	10	5.0	5.0
Sildenafil Powder,	24	5.0	5.0
Sotalol Hydrochloride	11	4.9	4.9
Instalax Polyethylene Glycol 3350	8	4.7	4.7
Polyethylene Glycol 400	8	4.6	4.6
Azelastine	11	4.5	4.5
Epoprostenol	8	4.5	4.5
Tafamidis	7	4.4	4.4
Sildenafil	34	4.3	4.3
Selexipag	14	4.0	4.0
Amlodipine Besylate And Valsartan	6	4.0	4.0
Tiotropium Bromide	69	3.8	3.8
Macitentan	35	3.7	3.7
Levodopa	6	3.6	3.6
Pertuzumab	13	3.5	3.5
Dofetilide	5	3.5	3.5
Apixaban	31	3.4	3.4
Dabigatran Etexilate Mesylate	33	3.4	3.4
Trastuzumab	31	3.3	3.3
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	14	3.3	3.3
Ticagrelor	14	3.2	3.2
Dabigatran Etexilate	33	3.1	3.1
Armodafinil	9	3.1	3.1
Interferon Beta-1A	78	3.0	3.0
Upadacitinib	32	2.9	2.9
Teriparatide	44	2.9	2.9
Nintedanib	12	2.8	2.8
Pirfenidone	15	2.7	2.7
Sodium Oxybate	23	2.6	2.6
Apalutamide	4	2.5	2.5
Diroximel Fumarate	4	2.5	2.5
Ambrisentan	39	2.3	2.3
Risankizumab-Rzaa	25	2.3	2.3
Peginterferon Beta-1A	4	2.2	2.2
Encorafenib	3	2.2	2.2
Remdesivir	4	2.2	2.2
Palivizumab	4	1.9	1.9
Enzalutamide	15	1.9	1.9
Relugolix	5	1.6	1.6
Lifitegrast	3	1.3	1.3
Abaloparatide	5	1.2	1.2
Pomalidomide	16	1.1	1.1
Evolocumab	18	0.8	0.8
Cinacalcet Hydrochloride	5	0.8	0.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.